322 related articles for article (PubMed ID: 29192326)
21. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
[TBL] [Abstract][Full Text] [Related]
22. GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
Joha S; Nugues AL; Hétuin D; Berthon C; Dezitter X; Dauphin V; Mahon FX; Roche-Lestienne C; Preudhomme C; Quesnel B; Idziorek T
Oncogene; 2012 Mar; 31(11):1419-30. PubMed ID: 21804606
[TBL] [Abstract][Full Text] [Related]
23. Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms.
Hirano I; Nakamura S; Yokota D; Ono T; Shigeno K; Fujisawa S; Shinjo K; Ohnishi K
J Biol Chem; 2009 Aug; 284(33):22155-22165. PubMed ID: 19261608
[TBL] [Abstract][Full Text] [Related]
24. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Müller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL
Blood; 2012 Feb; 119(6):1501-10. PubMed ID: 22184410
[TBL] [Abstract][Full Text] [Related]
25. Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.
Kurzrock R; Talpaz M; Li L; Estrov Z
Leuk Lymphoma; 2006 Aug; 47(8):1651-64. PubMed ID: 16966279
[TBL] [Abstract][Full Text] [Related]
26. Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.
Huang Q; Yang Y; Li X; Huang S
Tumour Biol; 2011 Dec; 32(6):1191-7. PubMed ID: 21892628
[TBL] [Abstract][Full Text] [Related]
27. Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation.
Monteghirfo S; Tosetti F; Ambrosini C; Stigliani S; Pozzi S; Frassoni F; Fassina G; Soverini S; Albini A; Ferrari N
Mol Cancer Ther; 2008 Sep; 7(9):2692-702. PubMed ID: 18790751
[TBL] [Abstract][Full Text] [Related]
28. Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia.
Sears D; Luong P; Yuan M; Nteliopoulos G; Man YK; Melo JV; Basu S
Cell Death Dis; 2010 Nov; 1(11):e93. PubMed ID: 21368869
[TBL] [Abstract][Full Text] [Related]
29. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies.
Akahane D; Tauchi T; Okabe S; Nunoda K; Ohyashiki K
Cancer Sci; 2008 Jun; 99(6):1251-7. PubMed ID: 18429956
[TBL] [Abstract][Full Text] [Related]
30. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
Kharas MG; Janes MR; Scarfone VM; Lilly MB; Knight ZA; Shokat KM; Fruman DA
J Clin Invest; 2008 Sep; 118(9):3038-50. PubMed ID: 18704194
[TBL] [Abstract][Full Text] [Related]
31. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.
Warmuth M; Danhauser-Riedl S; Hallek M
Ann Hematol; 1999 Feb; 78(2):49-64. PubMed ID: 10089019
[TBL] [Abstract][Full Text] [Related]
32. Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.
Deutsch E; Maggiorella L; Wen B; Bonnet ML; Khanfir K; Frascogna V; Turhan AG; Bourhis J
Br J Cancer; 2004 Nov; 91(9):1735-41. PubMed ID: 15494718
[TBL] [Abstract][Full Text] [Related]
33. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.
Kim JH; Chu SC; Gramlich JL; Pride YB; Babendreier E; Chauhan D; Salgia R; Podar K; Griffin JD; Sattler M
Blood; 2005 Feb; 105(4):1717-23. PubMed ID: 15486067
[TBL] [Abstract][Full Text] [Related]
34. Regulation of hTERT by BCR-ABL at multiple levels in K562 cells.
Chai JH; Zhang Y; Tan WH; Chng WJ; Li B; Wang X
BMC Cancer; 2011 Dec; 11():512. PubMed ID: 22151181
[TBL] [Abstract][Full Text] [Related]
35. An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
Xing H; Liu T; Meng W; Gong Y
Int J Lab Hematol; 2011 Apr; 33(2):176-81. PubMed ID: 20942869
[TBL] [Abstract][Full Text] [Related]
36. The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells.
Ye YB; Lin JY; Chen Q; Liu F; Chen HJ; Li JY; Liu WQ; Garbay C; Vidal M
Biochem Pharmacol; 2008 Jun; 75(11):2080-91. PubMed ID: 18455151
[TBL] [Abstract][Full Text] [Related]
37. Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway.
Keeshan K; Cotter TG; McKenna SL
Br J Haematol; 2003 Oct; 123(1):34-44. PubMed ID: 14510940
[TBL] [Abstract][Full Text] [Related]
38. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings.
Zhu Jf; Li Zj; Zhang Gs; Meng K; Kuang Wy; Li J; Zhou Xf; Li Rj; Peng Hl; Dai Cw; Shen JK; Gong Fj; Xu Yx; Liu Sf
PLoS One; 2011; 6(8):e23720. PubMed ID: 21887305
[TBL] [Abstract][Full Text] [Related]
39. Critical role for Gab2 in transformation by BCR/ABL.
Sattler M; Mohi MG; Pride YB; Quinnan LR; Malouf NA; Podar K; Gesbert F; Iwasaki H; Li S; Van Etten RA; Gu H; Griffin JD; Neel BG
Cancer Cell; 2002 Jun; 1(5):479-92. PubMed ID: 12124177
[TBL] [Abstract][Full Text] [Related]
40. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.
Pene-Dumitrescu T; Peterson LF; Donato NJ; Smithgall TE
Oncogene; 2008 Nov; 27(56):7055-69. PubMed ID: 18794796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
